



# Biotech Daily

Monday January 23, 2012

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH EVEN: OPTISCAN UP 13%, SUNSHINE DOWN 7.5%**
- \* **SIRTEX: Q2 UNIT SALES UP 22%, 30 QUARTERS IN A ROW**
- \* **PATRY'S EX-CEO DAN DEVINE INCREASES, DILUTED BELOW 5%**
- \* **TWO PERTH EXECUTIVES CEMENT FERMISCAN MOVE TO MINING**
- \* **LANG WALKER, COMPANIES INCREASE TO 8% OF QRX**
- \* **ATCOR, SUNTECH MEDICAL STRATEGIC ALLIANCE**
- \* **CORRECTION: CBIO**
- \* **CONSEGNA REQUESTS CAPITAL RAISING TRADING HALT**

## MARKET REPORT

The Australian stock market fell 0.34 percent on Monday January 23, 2012 with the S&P ASX 200 down 14.5 points to 4,225.1 points.

Thirteen of the Biotech Daily Top 40 stocks were up, 13 fell, nine traded unchanged and five were untraded. All three Big Caps fell.

Optiscan was the best, up 1.5 cents or 13.0 percent to 13 cents with 155,000 shares traded.

Alchemia and Anteo climbed more than six percent; Genetic Technologies was up five percent; Neuren was up 4.35 percent; Psivida was up 3.45 percent; Patrys rose 2.7 percent; Bionomics and Tissue Therapies were up more than one percent; with Nanosonics, Pharmaxis, QRX and Reva up by less than one percent.

Sunshine Heart led the falls, down 0.3 cents or 7.5 percent to 3.7 cents, with 93,000 shares traded, followed by Prana down 6.1 percent to 15.5 cents with 72,850 shares traded.

Benitec and Circadian fell more than four percent; Impedimed lost 3.3 percent; Allied Health, Clinuvel, Phosphagenics, Prima and Sirtex shed more than two percent; Mesoblast was down 1.7 percent; with Biota, Cochlear, CSL, Resmed and Starpharma down by less than one percent.

### SIRTEX MEDICAL

Sirtex says that sales of its SIR-Spheres microspheres grew 21.6 per cent for the three months to December 31, 2011 compared to the previous corresponding period.

Sirtex did not provide the value of the increased sales, but last year said that dose sales of the Sir-Spheres treatment for liver cancer were up 19 percent for the 12 months to 4,977 doses, with product revenue up nine percent to \$70.3 million (BD: Aug 25, 2011).

Today, the company said that dose sales grew in all regions, with the US up 31.4 percent, Asia Pacific up 37.5 percent and Europe up one percent "despite the financial uncertainty".

Sirtex said it had achieved 30 consecutive quarters of positive growth since 2004.

Sirtex chief executive officer Gilman Wong said the results "show continued sustained growth and strong demand for our targeted liver cancer therapy by a growing number of medical professionals worldwide seeking an effective way to treat liver cancer patients".

Sirtex fell 13 cents or 2.8 percent to \$4.50.

### PATRYS

Former Patrys chief executive officer Dan Devine has increased his holding but has been diluted below the five percent for a substantial holding in the company.

Mr Devine said he acquired a total of 1,666,667 shares on December 6, 2011 and January 19, 2012 for \$50,000 or three cents a share.

In his previous substantial shareholder notice in July 2007, Mr Devine said he held 14,327,272 shares.

Today Mr Devine said that number of shares equated to about 6.17 percent of the company, but he was diluted below five percent in last month's \$3.4 million capital raising at three cents a share (BD: Dec 2, 2011).

Patrys was up 0.1 cents or 2.7 percent to 3.8 cents.

### FERMISCAN

Fermiscan has appointed director Richard (Dick) Wright as managing director and Giuseppe Leone as operating officer.

Fermiscan said the two Perth-based appointments would "further strengthen efforts in identifying opportunities in the resources sector for ... wholly owned subsidiary FHL Mining Services Pty Ltd.

In November 2011 Fermiscan said that a business review determined the mining services industry "presents a number of opportunities and a strong future" (BD: Nov 22, 2011).

Over several years Fermiscan failed to commercialize Prof Veronica James' x-ray diffraction test for breast cancer and acquired then sold the Sydney Breast Clinic and the rights to the intellectual property associated with the test.

Fermiscan raised funds for a number of purposes including further development of the breast cancer diagnostic (BD: Jan 16, Aug 3, 2011) and in 2009 initiated legal actions against Prof James, with the New South Wales Supreme Court finding in Prof James favor (BD: Jun 5, Nov, 11, Dec 16, 2009).

Today Fermiscan said Mr Wright was "one of Australia's most experienced and respected leaders in mining and oil and gas development" and that Mr Leone had more than 15 years experience in non-mechanical industrial services for the oil and gas, power generation, chemical, minerals and mining sectors.

Fermiscan was up 0.2 cents or 14.3 percent to 1.6 cents with 16.0 million shares traded.

### QRX PHARMA

Lang Walker and three related companies have increased their holding in QRX from 9,385,420 shares (6.51%) to 12,017,007 shares (8.33%).

The companies, Auckland Trust Co, Werft Pty Ltd, Tessroff Pty Ltd and Langley Alexander Walker, bought the 2,631,587 shares between November 30, 2011 and January 20, 2012 for \$3,779,911 or an average price of \$1.44 a share.

QRX was up one cent or 0.7 percent to \$1.48.

### ATCOR MEDICAL

Atcor it has formed a strategic alliance with US partner Suntech Medical to improve blood pressure measurement and overall cardiovascular assessment and management.

Atcor said the alliance combined its Sphygmocor non-invasive measurement of central aortic blood pressure and Suntech's expertise in motion-tolerant and other application-specific blood pressure measurement technologies.

Last year Atcor announced a clinical trials distribution and data management agreement with the North Carolina-based Suntech" (BD: Jul 27, 2011)

Atcor said at that time that along with its Sphygmocor systems, it would offer trial sponsors the Suntech Oscar 2 ambulatory blood pressure monitor, the only device that has been clinically validated to all three internationally recognized standards.

Today, Atcor said that together, the companies would develop and deliver new blood pressure monitoring products for patient diagnosis, hypertension management and research.

Suntech chief executive officer Dayn McBee said that Atcor's Sphygmocor systems "have become the gold standard for measuring central aortic blood pressure and arterial stiffness".

Atcor chief executive officer Duncan Ross said the alliance was "an important step towards developing improved and more comprehensive capabilities to assess cardiovascular disease progression and therapeutic efficacy".

Atcor was unchanged at nine cents.

### CBIO

Yesterday's Summer Catch-Up Edition referred to CBio acting managing-director Helen Cameron as the company's interim chief executive officer and in a headline as CEO.

Ms Cameron has told Biotech Daily that her position is "acting managing-director".

We apologize for the error.

The sub-editor has been granted a conditional pardon on his first day back at work.

CBio fell 0.4 cents or four percent to 9.6 cents.

### CONSEGNA

Consegna has requested a trading halt "pending an announcement in relation to a capital raising".

Trading will resume on January 25, 2012 or on an earlier announcement.

Consegna last traded at 4.4 cents.